Research
Hormonal
Steatosis biomarkers (FLI, NAFLD-LFS, HSI, VAI, TyG) are strongly correlated with insulin resistance (HOMA-IR) independently of the actual amount of liver fat.
These tests are best used to assess your overall metabolic risk (insulin resistance) rather than just liver fat. A high score suggests you are at higher risk for diabetes and cardiovascular issues, regardless of how much fat is actually in your liver.
GoodSupportsHIGH confidence
All the five steatosis biomarkers were significantly correlated with insulin resistance as assessed with HOMA-IR independently from the histological grades of steatosis.
Why this rating
Large cohort, multiple linear regression controlling for histological steatosis.
Source
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
Larysa Fedchuk et al. · Alimentary Pharmacology & Therapeutics · 2014
DOI 10.1111/apt.12963
cohort · n=324Cited 509×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Noninvasive steatosis biomarkers (FLI, NAFLD-LFS, HSI, VAI, TyG) accurately diagnose the presence of hepatic steatosis but fail to quantify its severity, rendering them unsuitable for monitoring treatment-induced changes in liver fat.Good
- Fibrosis and inflammation significantly confound steatosis biomarkers, causing them to yield higher values in patients with advanced fibrosis or NASH even when the amount of liver fat is similar.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →